• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Lexaria Bioscience Corp. - Warrant (NQ:LEXXW)

    0.0062 -0.0037 (-37.37%)
    Streaming Delayed Price Updated: 2:16 PM EST, Jan 8, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 58,117
    Open 0.0043
    Bid (Size) 0.0061 (100)
    Ask (Size) 0.0062 (24,900)
    Prev. Close 0.0099
    Today's Range 0.0043 - 0.0080
    52wk Range 0.0034 - 1.310
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4
    Via ACCESS Newswire
    News headline image
    Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4
    Via ACCESS Newswire

    Performance

    YTD
    -31.9%
    -31.9%
    1 Month
    -73.0%
    -73.0%
    3 Month
    -84.5%
    -84.5%
    6 Month
    -95.9%
    -95.9%
    1 Year
    -99.0%
    -99.0%

    More News

    Read More
    News headline image
    Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
    Via ACCESS Newswire
    News headline image
    Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
    Via ACCESS Newswire
    News headline image
    Lexaria Attending BIO International Convention
    Via ACCESS Newswire
    News headline image
    The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience
    Via ACCESS Newswire
    News headline image
    Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
    Via ACCESS Newswire
    News headline image
    Lexaria Bioscience Corp. Provides Strategic Update
    Via ACCESS Newswire
    News headline image
    Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
    Via ACCESS Newswire
    News headline image
    Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
    Via ACCESS Newswire
    News headline image
    Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain
    Via ACCESS Newswire
    News headline image
    Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference
    Via ACCESS Newswire
    News headline image
    Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone
    Via ACCESS Newswire
    News headline image
    GLP-1 "Arms Race" Broadens to Include Dozens of Companies
    Via ACCESS Newswire
    News headline image
    Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study
    Via ACCESS Newswire
    News headline image
    Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry
    Via ACCESS Newswire
    News headline image
    Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide
    Via ACCESS Newswire
    News headline image
    Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule
    Via ACCESS Newswire
    News headline image
    Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company
    Via ACCESS Newswire
    News headline image
    Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock
    Via ACCESS Newswire
    News headline image
    Lexaria Announces $2 Million Registered Direct Offering of Common Stock
    Via ACCESS Newswire
    News headline image
    Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology
    Via ACCESS Newswire
    News headline image
    Lexaria Updates its Ongoing Human Study GLP-1-H24-4
    Via ACCESS Newswire
    News headline image
    Lexaria's Human GLP-1 Study #5 Begins Dosing
    Via ACCESS Newswire
    News headline image
    Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R)
    Via ACCESS Newswire

    Frequently Asked Questions

    Is Lexaria Bioscience Corp. - Warrant publicly traded?
    Yes, Lexaria Bioscience Corp. - Warrant is publicly traded.
    What exchange does Lexaria Bioscience Corp. - Warrant trade on?
    Lexaria Bioscience Corp. - Warrant trades on the Nasdaq Stock Market
    What is the ticker symbol for Lexaria Bioscience Corp. - Warrant?
    The ticker symbol for Lexaria Bioscience Corp. - Warrant is LEXXW on the Nasdaq Stock Market
    What is the current price of Lexaria Bioscience Corp. - Warrant?
    The current price of Lexaria Bioscience Corp. - Warrant is 0.0062
    When was Lexaria Bioscience Corp. - Warrant last traded?
    The last trade of Lexaria Bioscience Corp. - Warrant was at 01/08/26 02:16 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.